Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Improving glioblastoma multiforme (GBM) treatment with radio-chemotherapy remains a challenge. Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration. The present study assessed the combination of radiotherapy (60 Gy/30 fractions/40 days) and topotecan (0.9 mg/m(2)/day on days 1-5 on weeks 1, 3 and 5) in 50 adults with histologically proven and untreated GBM. The incidence of non-hematological toxicities was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly lymphopenia and neutropenia). Partial response and stabilization rates were 2% and 32%, respectively, with an overall time to progression of 12 weeks. One-year overall survival (OS) rate was 42%, with a median OS of 40 weeks. Topotecan in combination with radiotherapy was well tolerated. However, while response and stabilization concerned one-third of the patients, the study did not show increased benefits in terms of survival in patients with unresectable GBM.
Lesimple
Thierry
T
Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. lesimple@rennes.fnclcc.fr
Riffaud
Laurent
L
Frappaz
Didier
D
Ben Hassel
Mohamed
M
Gédouin
Daniel
D
Bay
Jacques-Olivier
JO
Linassier
Claude
C
Hamlat
Abderrahmane
A
Piot
Gilles
G
Fabbro
Michel
M
Saïkali
Stéphan
S
Carsin
Béatrice
B
Guégan
Yvon
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004827:Epilepsy / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D013997:Time Factors; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
D000970:Antineoplastic Agents; D019772:Topotecan